11/11
11:49 am
prld
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD) [Yahoo! Finance]
Low
Report
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD) [Yahoo! Finance]
11/8
12:31 pm
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
11/6
04:22 pm
prld
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/6
04:05 pm
prld
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/28
08:25 am
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Neutral
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
10/24
07:30 am
prld
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
Medium
Report
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
10/9
07:30 am
prld
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
Medium
Report
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
9/20
05:55 am
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) was upgraded by analysts at HC Wainwright from a "hold" rating to a "strong-buy" rating.
Neutral
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) was upgraded by analysts at HC Wainwright from a "hold" rating to a "strong-buy" rating.
9/16
10:55 am
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $7.00 price target on the stock.
Low
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $7.00 price target on the stock.
9/16
08:03 am
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
9/13
10:00 am
prld
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
High
Report
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
9/10
08:01 am
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
9/9
07:30 am
prld
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
Low
Report
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
8/29
10:29 am
prld
MSD discontinues two Phase III Keytruda trials New Strong Buy Stocks for August 29th [Yahoo! Finance]
Low
Report
MSD discontinues two Phase III Keytruda trials New Strong Buy Stocks for August 29th [Yahoo! Finance]